MedTrace Logo

STaged Interventional Strategies for Acute ST-seGment Elevation Myocardial Infarction Patient With Multi-vessel Disease（STAGED）

NCT04918030 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1586

Last updated 2025-12-12

No results posted yet for this study

Summary

An investigator-initiated, randomized, multicenter, two-arm, open-label study of consecutive patients presenting with STEMI and MVD Objectives: The present study aimed to investigate the difference in major adverse cardiac event (MACE) between Early staged PCI versus Late staged PCI groups among patients with ST-segment elevated myocardial infarction （STEMI and multi-vessel Disease（MVD) who underwent primary PCI using DES for culprit lesions.

Background: In patients with STEMI with MVD who underwent primary PCI, complete revascularization for non-culprit lesions has proved to reduce the risk of cardiovascular death and myocardial infarction. However, the ideal timing point for staged PCI for nonculprit lesions remains uncertain.

Conditions

  • STEMI
  • Multi Vessel Coronary Artery Disease
  • Percutaneous Coronary Intervention
  • AMI Patients With Multivessel Disease, Staged PCI

Interventions

PROCEDURE

Early staged PCI

After revascularization of the culprit lesion, all significant non-culprit vessel will be complete revascularzed during index the index procedure (7±3 day).

PROCEDURE

Late staged PCI

During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 30±15 days to undergo PCI of the other significant coronary lesions.

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    collaborator OTHER

  • Xiamen Cardiovascular Hospital, Xiamen University

    lead OTHER

Principal Investigators

  • Yan Wang, Dr · Clinical Trial Center of Xiamen Cardiovascular Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-11
Primary Completion
2025-02-01
Completion
2025-02-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04918030 on ClinicalTrials.gov